Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy

Frontiers in Pharmacology

Volumn 8, Issue FEB, 2017, Pages

  Kumar, Vivek ^a   Chaudhary, Neha ^a   Garg, Mohit ^a   Floudas, Charalampos S ^a   Soni, Parita ^a   Chandra, Abhinav B ^b  

^a MAIMONIDES MEDICAL CENTER   (United States)

^b Yuma Ag Center   (United States)

Author keywords

Checkpoint blockade; Immune related adverse events; Ipilimumab; IrAEs; Nivolumab; Pembrolizumab

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; ATEZOLIZUMAB; CYCLOPHOSPHAMIDE; DURVALUMAB; INFLIXIMAB; IPILIMUMAB; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; NIVOLUMAB; PEMBROLIZUMAB; PIDILIZUMAB; PREDNISONE; TICILIMUMAB;

ACUTE KIDNEY FAILURE; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOODY DIARRHEA; CANCER RECURRENCE; COLITIS; COMPUTER ASSISTED TOMOGRAPHY; CONJUNCTIVITIS; DERMATITIS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; ENDOCRINE DISEASE; EPISCLERITIS; GASTROINTESTINAL OBSTRUCTION; GUILLAIN BARRE SYNDROME; HEAD AND NECK CANCER; HEMOPHILIA A; HEPATITIS; HODGKIN DISEASE; HUMAN; HYPERBILIRUBINEMIA; HYPOPHYSITIS; HYPOTHYROIDISM; IMMUNE MEDIATED COLITIS; IMMUNE MEDIATED DERMATITIS; IMMUNE MEDIATED ENDOCRINOPATHY; IMMUNE MEDIATED HEPATITIS; IMMUNE MEDIATED INJURY; IMMUNE MEDIATED NEPHRITIS; IMMUNE MEDIATED NEUROLOGICAL DISEASE; IMMUNE MEDIATED PNEUMONITIS; IMMUNE MEDIATED RENAL DYSFUNCTION; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL NEPHRITIS; INTESTINE PERFORATION; KIDNEY DYSFUNCTION; KIDNEY METASTASIS; LIVER TOXICITY; MELANOMA; MESOTHELIOMA; MUCOSA INFLAMMATION; MYASTHENIA GRAVIS; MYELITIS; NEPHRITIS; NEUROLOGIC DISEASE; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; POLYMYOSITIS; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRURITUS; RASH; RHABDOMYOLYSIS; RHEUMATOID ARTHRITIS; SHORT SURVEY; SIDE EFFECT; SJOEGREN SYNDROME; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; UVEITIS;

EID: 85014218501     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2017.00049     Document Type: Short Survey

References (84)

1. Abdel-Rahman, O., and Fouad, M. (2016). Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Ther. Adv. Respir. Dis. 10, 183-193. doi: 10.1177/1753465816636557
2. Abu Samra, K., Valdes-Navarro, M., Lee, S., Swan, R., Foster, C. S., Anesi, S. D., et al. (2016). A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab. Eur. J. Ophthalmol. 26, e46-e48. doi: 10.5301/ejo.5000724
3. Ahmad, S., Lewis, M., Corrie, P., and Iddawela, M. (2012). Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma. J. Oncol. Pharm. Pract. 18, 287-292. doi: 10.1177/1078155211411001
4. Akhtari, M., Waller, E. K., Jaye, D. L., Lawson, D. H., Ibrahim, R., Papadopoulos, N. E., et al. (2009). Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 Antibody). J. Immunother. 32, 322-324. doi: 10.1097/CJI.0b013e31819aa40b
5. Albarel, F., Gaudy, C., Castinetti, F., Morange, I., Conte-Devolx, B., Grob, J. J., et al. (2015). Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur. J. Endocrinol. 172, 195-204. doi: 10.1530/EJE-14-0845
6. Armand, P., Nagler, A., Weller, E. A., Devine, S. M., Avigan, D. E., Chen, Y. B., et al. (2013). Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J. Clin. Oncol. 31, 4199-4206. doi: 10.1200/JCO.2012.48.3685
7. Arriola, E., Wheater, M., Galea, I., Cross, N., Maishman, T., Hamid, D., et al. (2016). Outcome and biomarker analysis from a multicenter phase 2 study of ipilimumab in combination with carboplatin and etoposide as first-line therapy for extensive-stage SCLC. J. Thor. Oncol. 11, 1511-1521. doi: 10.1016/j.jtho.2016.05.028
8. Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., et al. (2005). Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 23, 6043-6053. doi: 10.1200/JCO.2005.06.205
9. Barjaktarevic, I. Z., Qadir, N., Suri, A., Santamauro, J. T., and Stover, D. (2013). Organizing pneumonia as a side effect of ipilimumab treatment of melanoma. Chest 143, 858-861. doi: 10.1378/chest.12-1467
10. Berger, R., Rotem-Yehudar, R., Slama, G., Landes, S., Kneller, A., Leiba, M., et al. (2008). Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 14, 3044-3051. doi: 10.1158/1078-0432.CCR-07-4079
11. Berman, D., Parker, S. M., Siegel, J., Chasalow, S. D., Weber, J., Galbraith, S., et al. (2010). Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun. 10, 11.
12. Berthod, G., Lazor, R., Letovanec, I., Romano, E., Noirez, L., Mazza Stalder, J., et al. (2012). Pulmonary sarcoid-like granulomatosis induced by ipilimumab. J. Clin. Oncol. 30, e156-e159. doi: 10.1200/JCO.2011.39.3298
13. Bilen, M. A., Subudhi, S. K., Gao, J., Tannir, N. M., Tu, S.-M., and Sharma, P. (2016). Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. J. Immunother Cancer 4, 36. doi: 10.1186/s40425-016-0139-8
14. Borghaei, H., Paz-Ares, K. L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., et al. (2015). Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627-1639. doi: 10.1056/NEJMoa1507643
15. Brahmer, J., Reckamp, K. L., Baas, P., Crin, ò, L., Eberhardt, W. E., Poddubskaya, E., et al. (2015). Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123-135. doi: 10.1056/NEJMoa1504627
16. Calabro, L., Morra, A., Fonsatti, E., Cutaia, O., Fazio, C., Annesi, D., et al. (2015). Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. Lancet Respir Med. 3, 301-309. doi: 10.1016/S2213-2600(15)00092-2
17. Callahan, M. K., Yang, A., Tandon, S., Xu, Y., Subudhi, S. K., Roman, R. A., et al. (2011). Evaluation of serum IL-17 levels during ipilimumab therapy: correlation with colitis. J. Clin. Oncol. 29s:2505.
18. Cappelli, L. C., Gutierrez, A. K., Baer, A. N., Albayda, J., Manno, R. L., Haque, U., et al. (2017). Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann. Rheum. Dis. 76, 43-50. doi: 10.1136/annrheumdis-2016-209595
19. Corsello, S. M., Barnabei, A., Marchetti, P., De Vecchis, L., Salvatori, R., and Torino, F. (2013). Endocrine side effects induced by immune checkpoint inhibitors. J. Clin. Endocrinol. Metab. 98, 1361-1375. doi: 10.1210/jc.2012-4075
20. Cortazar, F. B., Marrone, K. A., Troxell, M. L., Ralto, K. M., Hoenig, M. P., Brahmer, J. R., et al. (2016). Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 90, 638-647. doi: 10.1016/j.kint.2016.04.008
21. Cousin, S., and Italiano, A. (2016). Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities. Clin. Cancer Res. 22, 4550-4555. doi: 10.1158/1078-0432.CCR-15-2569
22. Delyon, J., Mateus, C., and Lambert, T. (2011). Hemophilia A induced by ipilimumab. N. Engl. J. Med. 365, 1747-1748. doi: 10.1056/NEJMc1110923
23. de Maleissye, M.-F., Nicolas, G., and Saiag, P. (2016). Pembrolizumab-Induced Demyelinating Polyradiculoneuropathy. N. Engl. J. Med. 375, 296-297. doi: 10.1056/NEJMc1515584
24. Du-Thanh, A., Pallure, V., Girard, C., Dereure, O., and Guillot, B. (2015). Clostridium difficile infection may loom behind ipilimumab-induced auto-immune colitis. Eur. J. Dermatol. 25, 344. doi: 10.1684/ejd.2015.2561
25. Eggermont, A. M., Chiarion-Sileni, V., Grob, J. J., Dummer, R., Wolchok, J. D., Schmidt, H., et al. (2016). Prolonged survival in stage III Melanoma with Ipilimumab adjuvant therapy. N. Engl. J. Med. 375, 1845-1855. doi: 10.1056/NEJMoa1611299
26. Eggermont, A. M., Chiarion-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J. D., Schmidt, H., et al. (2015). Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 16, 522-530. doi: 10.1016/S1470-2045(15)70122-1
27. Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., et al. (2016). Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016, 387, 1837-1846. doi: 10.1016/S0140-6736(16)00587
28. Ferris, R. L., Blumenschein, G. Jr., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., et al. (2016). Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 375, 1856-1867. doi: 10.1056/NEJMoa1602252
29. Gangadhar, T. C., and Vonderheide, R. H. (2014). Mitigating the toxic effects of anticancer immunotherapy. Nat. Rev. Clin. Oncol. 11, 91-99. doi: 10.1038/nrclinonc.2013.245
30. Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., et al. (2015). Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018-2028. doi: 10.1056/NEJMoa1501824
31. Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W. J., Kefford, R., et al. (2013). Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134-144. doi: 10.1056/NEJMoa1305133
32. Herbst, R. S., Baas, P., Kim, D., Felip, E., Pérez-Gracia, J. L., Han, J. Y., et al. (2016). Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387, 1540-1550. doi: 10.1016/S0140-6736(15)01281-7
33. Hodi, F., Lee, S., McDermott, D. F., Rao, U. N., Butterfield, L. H., Tarhini, A. A., et al. (2014). Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 312, 1744-1753. doi: 10.1001/jama.2014.13943
34. Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723. doi: 10.1056/NEJMoa1003466
35. Horvat, T. Z., Adel, N. G., Dang, T. O., Momtaz, P., Postow, M. A., Callahan, M. K., et al. (2015). Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center. J. Clin. Oncol. 33, 3193. doi: 10.1200/jco.2015.60.8448
36. Huillard, O., Bakalian, S., Levy, C., Desjardins, L., Lumbroso-Le Rouic, L., Pop, S., et al. (2014). Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review. Eur. Cancer J. 50, 638-648. doi: 10.1016/j.ejca.2013.10.016
37. Ibrahim, R., Berman, D., de Pril, V. V., Humphrey, R. W., Chen, T., Messina, M., et al. (2011). Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma. J. Clin. Oncol. 29 (abstract).
38. Izzedine, H., Gueutin, V., Gharbi, C., Mateus, C., Robert, C., Routier, E., et al. (2014). Kidney injuries related to ipilimumab. Invest. New Drugs 32, 769. doi: 10.1007/s10637-014-0092-7
39. Jaber, S. H., Cowen, E. W., Haworth, L. R., Booher, S. L., Berman, D. M., Rosenberg, S. A., et al. (2006). Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent. Arch. Dermatol. 142, 166-172. doi: 10.1001/archderm.142.2.166
40. Johncilla, M., Misdraji, J., Pratt, D. S., Agoston, A. T., Lauwers, G. Y., Srivastava, A., et al. (2015). Ipilimumab-associated Hepatitis: Clinico pathologic Characterization in a Series of 11 Cases. Am. J. Surg. Pathol. 39, 1075-1084. doi: 10.1097/PAS.0000000000000453
41. Johnson, D. B., Sullivan, R. J., Ott, P. A., Carlino, M. S., Khushalani, N. I., Ye, F., et al. (2015). Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune. JAMA Oncol. 2, 234-240. doi: 10.1001/jamaoncol.2015.4368
42. Kindler, H. L., Scherpereel, A., Calabrò, L., Aerts, J., Perez, S. C., Bearz, A., et al. (2016). Tremelimumab as second-or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study. J. Clin. Oncol. 34 (abstract).
43. Kong, B. Y., Micklethwaite, K. P., Swaminathan, S., Kefford, R. F., and Carlino, M. S. (2016). Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma. Melanoma Res. 26, 202-204. doi: 10.1097/CMR.0000000000000232
44. Langer, C. J. (2015). Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors. Am. J. Clin. Oncol. 38, 422-430. doi: 10.1097/coc.0000000000000059
45. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., et al. (2015). Combined nivolumab and ipilimumab or Monotherapy in Untreated Melanoma. N. Engl. J. Med. 373, 23-34. doi: 10.1056/NEJMoa1504030
46. Liao, B., Shroff, S., Kamiya-Matsuoka, C., and Tummala, S. (2014). Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro-oncology 16, 589-593. doi: 10.1093/neuonc/nou001
47. Massard, C., Gordon, M. S., Sharma, S., Rafii, S., Wainberg, Z. A., Luke, J., et al. (2016). Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J. Clin. Oncol. 34, 3119-3125. doi: 10.1200/JCO.2016.67.9761
48. Maur, M., Tomasello, C., Frassoldati, A., Dieci, M. V., Barbieri, E., Conte, P., et al. (2012). Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J. Clin. Oncol. 30, e76-e78. doi: 10.1200/JCO.2011.38.7886
49. Min, L., Hodi, F. S., Giobbie-Hurder, A., Ott, P. A., Luke, J. J., Donahue, H., et al. (2015). Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin. Cancer Res. 21, 749-755. doi: 10.1158/1078-0432.CCR-14-2353
50. Minor, D., Chin, K., and Kashani-Sabet, M. (2009). Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis. Cancer Biother. Radiopharm. 24, 321-325. doi: 10.1089/cbr.2008.0607
51. Momtaz, P., Park, V., Panageas, K. S., Postow, M. A., Callahan, M., Wolchok, J. D., et al. (2015). Safety of Infusing ipilimumab Over 30 Minutes. J. Clin. Oncol. 33, 3454-3458. doi: 10.1200/JCO.2015.61.0030
52. Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., et al. (2015). Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann. Oncol. 26, 2375. doi: 10.1093/annonc/mdv383
53. Nanda, R., Chow, L. Q., Dees, E. C., Berger, R., Gupta, S., Geva, R., et al. (2016). Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J. Clin. Oncol. 34, 2460-2467. doi: 10.1200/JCO.2015.64.8931
54. National Cancer Institute (2009). Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Available online at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference:5x7.pdf
55. Oble, D. A., Mino-Kenudson, M., Goldsmith, J., Hodi, F. S., Seliem, R. M., Dranoff, G., et al. (2008). Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis. Am. J. Surg. Pathol. 32, 1130-1137. doi: 10.1097/PAS.0b013e31817150e3
56. Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., et al. (2015). Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372, 2006-2017. doi: 10.1056/NEJMoa1414428
57. Postow, M., and Wolchok, J. (2016). "Toxicities associated with checkpoint inhibitor immunotherapy," in UpToDate, ed T. W. Post (Waltham, MA). (Accessed: August 1, 2016).
58. Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Coszi, T., Fülöp, A., et al. (2016). Pembrolizumab versus Chemotherapy for PD-L1-Positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823-1833. doi: 10.1056/NEJMoa1606774
59. Ribas, A., Hodi, F. S., Callahan, M., Konto, C., and Wolchok, J. (2013). Hepatotoxicity with combination of vemurafenib and ipilimumab. N. Engl. J. Med. 368, 1365-1366. doi: 10.1056/nejmc1302338
60. Ribas, A., Kefford, R., Marshall, M. A., Punt, C. J., Haanen, J. B., Marmol, M., et al. (2013). Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J. Clin. Oncol. 31, 616-622. doi: 10.1200/JCO.2012.44.6112
61. Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., et al. (2017). Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389, 255-265. doi: 10.1016/S0140-6736(16)32517-X
62. Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., et al. (2015). Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 16, 257-265. doi: 10.1016/S1470-2045(15)70054-9
63. Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., et al. (2015). Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320-330. doi: 10.1056/NEJMoa1412082
64. Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., et al. (2015). Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521-2532. doi: 10.1056/NEJMoa1503093
65. Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., et al. (2011). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517-2526. doi: 10.1056/NEJMoa1104621
66. Rosenberg, J. E., Jean, H., Tom, P., van der Heijden, M. S., Balar, A. V., Necchi, A., et al. (2016). Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909-1920. doi: 10.1016/S0140-6736(16)00561-4
67. Ryder, M., Callahan, M., Postow, M., Wolchok, J., and Fagin, J. A. (2014). Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr. Relat. Cancer 21, 371-381. doi: 10.1530/ERC-13-0499
68. Schindler, K., Harmankaya, K., and Kuk, D. (2014). Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab. J. Clin. Oncol. 32:5s (abstract).
69. Seiwert, T. Y., Burtness, B., Mehra, R., Weiss, J., Berger, R., Eder, J. P., et al. (2016). Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 17, 956-965. doi: 10.1016/S1470-2045(16)30066-3
70. Shahabi, V., Berman, D., Chasalow, S. D., Wang, L., Tsuchihashi, Z., Hu, B., et al. (2013). Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events. J. Transl. Med. 11:75. doi: 10.1186/1479-5876-11-75
71. Tarhini, A. A., Cherian, J., Moschos, S. J., Tawbi, H. A., Shuai, Y., Gooding, W. E., et al. (2012). Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J. Clin. Oncol. 30, 322-328. doi: 10.1200/JCO.2011.37.5394
72. Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., et al. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443. doi: 10.1056/NEJMoa1200690
73. Topalian, S. L., Sznol, M., McDermott, D., Kluger, F. H. M., Carvajal, R. D., Sharfman, W. H., et al. (2014). Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32, 1020-1030. doi: 10.1200/JCO.2013.53.0105
74. Villadolid, J., and Amin, A. (2015). Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl. Lung Cancer Res. 4, 560-575. doi: 10.3978/j.issn.2218-6751.2015.06.06
75. Weber, J. (2009). Ipilimumab: Controversies in its development, utility, and autoimmune adverse events. Cancer Immunol. Immunother. 58, 823-830. doi: 10.1007/s00262-008-0653-8
76. Weber, J., Hamid, O., Amin, A., Masson, E., Goldberg, S. M., Williams, D., et al. (2013). Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. Cancer Immun. 13, 7
77. Weber, J. S. (2012). Practical Management of immune related adverse events from immune checkpoint protein antibodies for the oncologist. Am. Soc. Clin. Oncol. Educ. Book 2012, 174-177. doi: 10.14694/EdBook_AM.2012.32.174
78. Weber, J. S., Kudchadkar, R. R., and Yu, B. (2013). Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or-naive melanoma. J. Clin. Oncol. 31, 4311. doi: 10.1200/jco.2013.51.4802
79. Weber, J. S., Yang, J. C., Atkins, M. B., and Disis, M. L. (2015). Toxicities of Immunotherapy for the Practitioner. J. Clin. Oncol. doi: 10.1200/jco.2014.60.0379
80. Weber, J., Thompson, J. A., Hamid, O., Minor, D., Amin, A., Ron, I., et al. (2009). A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin. Cancer Res. 15, 5591-5598. doi: 10.1158/1078-0432.CCR-09-1024
81. Westin, J. R., Chu, F., Zhang, M., Fayad, L. E., Kwak, L. W., Fowler, N., et al. (2014). Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 15, 69-77. doi: 10.1016/S1470-2045(13)70551-5
82. Wilgenhof, S., and Neyns, B. (2011). Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient. Ann. Oncol. 22, 991-993. doi: 10.1093/annonc/mdr028
83. Williams, T. J., Benavides, D. R., Patrice, K. A., Dalmau, J. O., de ávila, A. L., Le, D. T., et al. (2016). Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol. 73, 928-933. doi: 10.1001/jamaneurol.2016.1399
84. Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., et al. (2010). Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 11, 155-164. doi: 10.1016/S1470-2045(09)70334-1